2002
 
 -The Biocon India group promoter of Biocon India Ltd.  Ms Kiran
 Mazumdar Shaw, Chairman and Managing Director of Biocon India Group.
 
 
 -Biocon India appointed DSP Merrill Lynch and Kotak Mahindra for its
 Rs 150-crore IPO scheduled for June next year. Biocon-Shantha
 Biotech, the 50:50 joint venture between Biocon India and Shantha
 Biotechnics, focuses on the domestic and global human insulin markets
 by maximizing on R&D manufacturing and regulatory capacities of the
 two companies.
 
 2003
 
 -ICICI Venture offloads 10-pc stake in Biocon
 
 2004
 
 -Clinigene International inaugurates human pharmacology unit for
 clinical trials
 
 -Comes out with an Initial Public Offering (IPO) of 10 million shares
 at a price of Rs 315 per share for a face value of Rs 5 per share
 which constitutes 10% of the post-issue capital (Rs 100 crore),
 listed at Rs 425
 
 -Biocon Ltd has entered into a nine-year export contract with US
 major Bristol-Myers Squibb Co to supply the bulk form of its
 recombinant human insulin
 
 -Biocon forays into lifestyle drugs market
 
 -Biocon's clinical research arm, Clinigene International Pvt Ltd.
 re-accredited by the College of American Pathologists (CAP) following
 a recent inspection
 
 -Biocon Ltd has informed that in an unusual commercial transaction
 between Cuba and USA, a Californian Biotechnology Company, CancerVax
 Corporation received a rare US Government approval to License three
 experimental cancer drugs from a leading Cuban Institute (CIMAB)
 
 -Biocon said on July 26 that its Cuban partner CIMAB (Centre for
 Molecular Immunology) in the joint venture with Biocon
 Biopharmaceuticals will be able to license out three experimental
 cancer drugs to a Californian Biotechnology company, CancerVax
 Corporation
 
 -Biocon, Syngene enters into Research Agreement with Novartis
 Institutes for Biomedical Research Inc
 
 -Biocon unveils new bio insulin
 
 2005
 
 Biocon signs MoU with Karolinska Institute.
 
 -Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, has been honoured with
 the Corporate Leadership Award 2005 of the American India Foundation
 (AIF)
 
 -Biocon signs Licensing agreement with Bentley Pharmaceuticals Inc.
 
 2006
 
 -Biocon ties up with ICICI Prudential Life Insurance
 
 -Biocon concludes Phase-IV trials of Insugem
 
 2007
 
 -Biocon Ltd and Abu Dhabi based pharmaceutical company Neopharma have
 signed an MOU to establish a JV to manufacture and market a range of
 Bio-pharmaceuticals for the GCC countries (Gulf Cooperation
 Council).
 
 -Biocon Ltd on March 14, 2007 has announced that its subsidiary
 Company Syngene has entered into a research partnership with
 Bristol-Myers Squibb.
 
 -Biocon signs MOU with Neopharma for a JV
 
 2008
 
 -The Company has issued Bonus Shares in the Ratio of 1:1.
 
 2009
 
 - Biocon and Amylin Pharmaceuitcals Inc have entered into an
 exclusive agreement to jointly develop, commercialise and manufacture
 a new peptide therapeutic for potential treatment of diabetes. The two
 companies will share development costs.
 
 -Biocon launches BASALOG - long lasting basal insulin for Type 1 &
 Type 2 Diabetics
 
 -Biocon joins hands with Amylin Pharmaceuticals
 
 -Biocon inks partnership with ISB to launch the Biocon Cell for
 Innovation Management
 
 2010
 
 - Biocon has launched its new 'comprehensive care' division,
 dedicated to provide affordable solutions to critical illnesses such
 as nosocomial infections, post surgical complications, trauma and
 medical emergencies.
 
 - Biocon has signed an agreement with Teleradiology Solutions to
 provide teleradiology reporting services to Clinigene, Biocon's
 clinical research arm.